Sentences with phrase «future clinical studies»

«If future clinical studies demonstrate that this strategy is effective, we hope our work will lead to development of new, low - cost atopic dermatitis therapies that do not require daily application,» Myles, an NIAID researcher, said in an institute news release.

The effectiveness of the concomitant approach demonstrated in this definitive study also indicates the importance of future clinical studies that seek greater clinical benefit through the study of multi-targeted approaches in earlier disease settings.»

Stegmaier notes that over the course of this research, the team has developed a suite of tools that could prove invaluable for future clinical studies of treatments with SYK inhibitors or SYK inhibitors in combination with FLT3 inhibitors.

The current model combines data from individuals relating to all these factors, making it more accurate than previous models and easier to verify with future clinical studies.

If future clinical studies show comparable findings in patients, Terry Clyburn, M.D., professor of orthopaedics and director of Total Joint Services at the UTHealth Medical School, said antibiotic - containing microspheres could serve to prevent these rare but devastating and often hard - to - treat infections.

«Nevertheless, this study identified mechanisms suitable to explore damage and protection on the vasculature in humans, paving the way for future clinical studies.»

Not exact matches

Examples of forward - looking statements in this news release include statements regarding the effectiveness of the Company's products, the potential outcome of clinical studies, the future success of development activities and the future growth and operating and financial performance of the Company.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Mar. 18, 2013 — People suffering from complicated grief may have difficulty recalling specific events from their past or imagining specific events in the future, but not when those events involve the partner they lost, according to a new study published in Clinical Psychological Science, a journal of the Association for Psychological Science.

The collaborative study was developed from a meeting last August of sports medicine clinicians, researchers and a bioethicist to understand the current evidence risks and rewards and future directions of research and clinical practice for regenerative medicine therapies in youth sports.

And recently, the group has begun a clinical study to predict, after one treatment, how an individual's cancer will progress, and use that prediction to plan the future course of treatment.

«Given the relatively high incidence of low TSH levels in patients taking metformin, it is imperative that future studies assess the clinical consequences of this effect.»

The discovery of a treatment capable of blocking the mechanism responsible for the formation of metastasis and the existence of a family of promising compounds, is encouragement for their future assessment in a clinical study that aims to validate a preventive treatment against tumor metastasis.

Puneet Arora, an engaging physician who has studied at Indian and American universities and practiced medicine among America's underserved — and who currently is Amgen's director of clinical research — appeared on behalf of Immigration Voice, an organization of «legal high - skilled future Americans,» its Web site says.

«We are extremely encouraged by the results of this study and hope that this technology will be adapted for patients for testing in clinical trials in the not - too - distant future.»

«The study results elucidate the molecular mechanisms underlying disease progression in multiple sclerosis models, providing a basis for future clinical trials to determine safety and efficacy of these chemical agents in humans with demyelinating disorders,» says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.

Future studies will examine in more detail the nature of these impairments and how they might affect clinical symptoms and school performance.

«Overall the turnaround for sample analyses fit a relevant clinical window for future comparative oncology trials to model human PMed advancements,» said Dr. William Hendricks, a TGen Staff Scientist and another author of the study.

«This study highlights the importance of confirming the validity of potential biomarkers in a relevant, large animal model and will be useful in the design of future clinical trails,» commented lead investigator Stephen J. Kolb, MD, PhD, Associate Professor, Department of Neurology and Biological Chemistry & Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH.

To avoid future ambiguities within clinical research, the researchers provide four considerations to inform study design.

Researchers say these results have implications for understanding disease origin rather than for clinical risk prediction and future studies should focus on the mechanisms underlying the relationship between childhood height and later stroke.

«This study shines a light on the pathogenesis of inflammatory bowel disease and offers a positive impact on its future clinical management,» says Liu.

White and colleagues will work with other collaborators at the Cancer Institute to develop early - phase patient clinical trials based on the findings from this study in the near future.

«While the pre-birth programming effect of PETN shows promise for future clinical implications, we must be careful about generalizing findings from animal studies to humans,» Li said.

In future studies, the researchers will characterize the interplay between the virus and host throughout evolution and continue to seek improved vectors for clinical applications.

But the implications of a recent study demonstrating this relationship are anything but simple and could influence both the design of future clinical trials and the goals of oncologists treating cancer.

The authors suggest that the findings of this study lay the groundwork for future sleep telemedicine research and clinical pathway development.

Dr Claire Smith, Consultant Neonatologist at the Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, added: «This study has the potential to provide real clinical benefits in the future.

The team used gene expression profiling and found that canine B - cell lymphoma expression profiles were similar in many ways to human B - cell lymphoma, thus paving the way for future studies, including therapeutic clinical trials in dogs and humans.

«The use of a mouse tumor - derived matrix would limit any future applications of these organoid technologies in humans, and this work opens the door to research directed specifically for clinical applications,» noted Asma Nusrat, study co-author and the Aldred Scott Warthin Professor and Director of Experimental Pathology in the University of Michigan's School of Medicine.

Shalowitz and colleagues suggest future studies should focus on defining areas with poor clinical outcomes attributed to geographic factors, and creating a comprehensive national, geographically - linked database on the utilization of gynecologic cancer care and clinical outcomes.

In future studies, scientists will test how the Tongue Drive System performs outside of the controlled clinical environment.

The authors note the small size of the study necessitates future research in clinical models and in men and women, particularly those who have sarcopenia.

«The underlying causes need to be investigated to help to identify practices and strategies to increase women's influence on and contributions to the evidence that will determine future healthcare policies and standards of clinical practice,» Giovanni Filardo, PhD, MPH, and his co-authors wrote in the paper, titled «Trends and comparison of female first authorship in high impact medical journals: observational study (1994 - 2014).»

«The majority of cancer patients we work with are excited to participate in clinical trials that could benefit future patient outcomes down the line,» says co-senior author Bryan Allen, who led the clinical side of the study.

Our findings clarify the disease's distinctive genetic signature, which should, in the future, help improve clinical trials, and lead to more targeted treatments,» said the study's lead author, Dr Jose Bras (UCL Institute of Neurology and Alzheimer's Society senior research fellow).

Our results suggest the need for future studies involving long - term ambulatory cardiac monitoring to better delineate the risk associated with transient vs persistent perioperative AF, as well as randomized clinical trials to determine optimal strategies for antithrombotic therapy in patients with perioperative AF and a significant burden of other risk factors for stroke,» the authors write.

These results provide important information for future disease research and clinical studies.

More generally, we hope that this study and its positive outcomes could encourage future investigations in different clinical settings.»

Using a biomaterial matrix of porous silk, the new, scalable system is capable of producing platelets for future clinical use and also provides a laboratory tissue system to advance study of blood platelet diseases.

Using a biomaterial matrix of porous silk, the new system is capable of producing platelets for future clinical use and also provides a laboratory tissue system to advance study of blood platelet diseases.

«The first clinical investigation of this drug in hemophilia A patients with or without FVIII inhibitors has already been implemented, and Phase III studies are being planned to start in the near future.»

In future studies, Sulchek and his team plan to test this approach and scale up the technology with clinical applications in mind.

Furthermore, results of this study provide essential directions to future pharmacogenomic research for reduction of ADR - related hospitalizations in Singapore,» said Professor Alexandre Chan, co-senior author of the British Journal of Clinical Pharmacology study.

The group hopes to examine the effect in clinical trials in the future, and plans to look at the function of the other six genes their study identified.

A Houston Methodist team led by Mauro Ferrari, PhD and Jenny Chang, MD has received funding from the U.S. Department of Defense to complete preclinical efficacy studies and a future clinical trial testing a breast cancer precision drug.

While we can not predict the outcome of any future safety or efficacy studies, this decision by FDA allowing clinical research to begin represents a major milestone in allowing us to hopefully provide answers to those critical questions in the future,» Conn said.

Ultimately, this will provide for current and future studies such as those that evaluate the correlation of biological markers with clinical variables and cancer outcomes, as well as those that identify interactions among biological markers.

The Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical trial is a current pilot study looking to identify potential biomarkers (measures) that can be used to evaluate SMA disease severity and future treatments.

The presentation, entitled «Ibudilast — Phosphodiesterase Type 4 Inhibitor — Bi-Modal Therapy with Riluzole in Early Cohort and Advanced Amyotrophic Lateral Sclerosis (ALS) Patients — Final Report and Future Directions «(Source) will be presented by principal investigator of the clinical study, Dr. Benjamin Rix Brooks, of the Carolinas HealthCare System's Neuromuscular / ALS - MDA Center at Carolinas HealthCare System Neurosciences Institute.